Partnering Contact About Us Pipeline Platform Clinical Trials Investors Careers Cardiovascular disease affects one in four people—and the number is growing. We are developing specialized, highly innovative therapies to meet this need. At PhaseBio, we are determined to overcome the lack of new treatment options for serious cardiovascular diseases and provide superior outcomes for patients and the healthcare system. We are driven by high-quality science, and we leverage our team’s deep expertise to rapidly develop a pipeline of unique medicines. OUR TEAM OUR PIPELINE OUR PLATFORM Copyright © 2021 PhaseBio Pharmaceuticals, Inc. | Privacy Policy | Cookie Policy | Accessibility We would like to set functionality and performance cookies to remember choices you make to give you better functionality and to make our site easier for you to navigate. By continuing to browse the site, you are agreeing to our use of cookies.I agreeLearn more

Skip to main navigation SITE - HEADER MENU Partnering Contact SITE - TOP NAV About Us Pipeline Platform Clinical Trials Investors Careers INVESTOR RELATIONS Overview News & Events Stock Information SEC Filings Corporate Governance Investor Resources INVESTORS Corporate Profile PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our proprietary elastin-like polypeptide (ELP) technology, which also serves as the engine for our preclinical pipeline. Stock Dec 2, 2021 12:43 PM EST CHANGE VOLUME Data Provided by Refinitiv. Minimum 15 minutes delayed. VIEW MORE Events Nov 15, 2021 at 12:30 PM EST Interim Analysis of Phase 3 REVERSE-IT Trial of Bentracimab Sep 13, 2021 at 7:00 AM EDT H.C. Wainwright Global Investment Conference VIEW MORE Latest News Dec 01, 2021 PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence Nov 18, 2021 PhaseBio Names Jonathan Birchall as Chief Commercial Officer Nov 15, 2021 PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding VIEW MORE INVESTOR RESOURCES Copyright © 2021 PhaseBio Pharmaceuticals, Inc. | Privacy Policy | Cookie Policy | Accessibility We would like to set functionality and performance cookies to remember choices you make to give you better functionality and to make our site easier for you to navigate. By continuing to browse the site, you are agreeing to our use of cookies. I agreeLearn more